2 June 2020 - Helsinn today announces that the U.S. FDA has approved the ready-to-dilute liquid formulation of Akynzeo (fosnetupitant/palonosetron) injection. 

This new liquid solution provides several improvements to storage and handling:

• Akynzeo injection does not require refrigeration at any stage of distribution, preparation or storage
• Akynzeo injection eliminates the need for reconstitution prior to dilution, reducing the preparation process for intravenous administration of Akynzeo to one step before use.
• Akynzeo injection may now be stored for up to 24 hours at room temperature after dilution, allowing more flexibility in preparation for busy clinicians

Read Helsinn press release